Azitra shares surge 67.18% intraday after announcing $31.4M securities purchase agreement with healthcare institutional investor, including $10.5M initial financing and $20.9M in potential warrants.

Azitra surged 67.18% intraday after announcing a $31.4 million securities purchase agreement with a healthcare institution, including $10.5 million in initial financing and up to $20.9 million in warrants. The company is a clinical-stage biopharmaceutical firm developing precision dermatology therapies, such as ATR-04 for EGFR inhibitor-related rashes.